Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDKN1A | P38936 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057460 | 0.98 | CDKN1A (0.52) | CDKN1AKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4056786 | 0.89 | KMT2A (0.52) | KMT2A | |
| SCHEMBL4061107 | 0.88 | KMT2A (0.53) | KMT2A | |
| SCHEMBL4060486 | 0.86 | ALDH1A1 (0.56) | CDKN1AKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4061524 | 0.85 | KMT2A (0.48) | KMT2A | |
| SCHEMBL4055673 | 0.84 | CDKN1A (0.52) | CDKN1AKMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL4059014 | 0.83 | KMT2A (0.46) | KMT2A | |
| SCHEMBL4060366 | 0.82 | CDKN1A (0.52) | CDKN1AKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3475690 | 0.79 | KMT2A (0.78) | CDKN1AKMT2A | |
| SCHEMBL4065925 | 0.79 | SMN1; SMN2 (0.49) | KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | claimed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | claimed |
| EP-1828199-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | claimed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006063732-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | GABBR1, CHRNA5, CHRNA3 | CDKN1A 2239/4885KMT2A 3171/4885POLB 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.